Solamargine, a derivative from the steroidal solasodine in Solanum species, exhibits anticancer activities in numerous types of cancer. Solamargine induces non-selective cytotoxicity and P-glycoprotein inhibition. Solamargine significantly inhibits migration and invasion of HepG2 cells by down-regulating MMP-2 and MMP-9 expression and activity^[1][2]. In Vitro: Solamargine (15 μg/ml; 72 hours) predominantly stimulates the cells of the G2/M phase to apoptosis^[3].
Solamargine (72 hours) dramatically inhibits the proliferation of SMMC-7721 and HepG2 cells in a dose- and time-dependent manner. The IC₅₀s are 9.21 and 19.88 μg/ml, respectively^[3]. In Vivo: Solamargine (10 mg/kg; intragastric administration; once daily for 8 days) exhibits an antitumor effect and promotes the apoptosis of GC in vivo^[4].